[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"immunology\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:immunology":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,49,77,106,131],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100574647","impaired-type-i-ifn-immunity-due-to-autoantibodies-or-a-genetic-defect-a-prospective-national-cohort-100574647",false,"NCT06762002","Impaired Type I IFN Immunity Due to Autoantibodies or a Genetic Defect: a Prospective National Cohort","COVIFERON","Inclusion Criteria:\n\n* Age \\>18 years\n* History of carrying 1) auto-Abs against type I IFNs or 2) IEI impairing the response to, or the production of, type I IFNs (IFN-I-IEI)\n* Affiliated to social security\n* Written informed consent\n\nExclusion Criteria:\n\n* Participation to an interventional clinical trial on a pharmacological treatment\n* Clinical condition leading to life expectancy less than 1 year\n* Subject to a legal protection measure (safeguard of justice, curatorship, tutorship)\n* Individuals deprived of freedom",true,"ALL","18 Years",{"count":20,"type":21},500,"ESTIMATED","3 Years","OBSERVATIONAL","The major role of human genetic factors in the immune response to infections is now well established, particularly for viral infections. In the context of the COVID-19 pandemic, the following results have identified 1) several inborn errors of immunity (IEI) affecting the response or production of type I interferons (type I IFNs) in around 4% of adult patients with severe clinical disease, and 2) the presence of type I IFN-neutralizing autoantibodies (auto-Abs) in around 15% of severe cases, and 20% of deaths. The investigators would like to carry out a longitudinal immunological and clinical follow-up study on a prospective cohort of patients with either a genetic defect affecting the type I IFN-dependent immune response, or anti-IFN-I auto-Abs, to monitor the incidence of infectious and\u002For autoimmune events in these individuals, the evolution of neutralizing power, and the kinetics of auto-Abs. This should lead to a better understanding of the prevention and management of these patients.\n\nThe research design is a national multicenter prospective cohort of adults with 1) anti-IFN-I auto-Abs or 2) IEI- IFN-I, with follow-up from 1 to 4 years. These individuals may be: 1) patients who have or have had clinical disease (related to COVID-19, other viral infections, autoimmune disorders); or 2) \"healthy\" participants (e.g. blood donors, relatives of an IEI patient).\n\nFollow-up will include:\n\n* yearly visits to the Clinical Investigation Center (CIC) or a clinical department with blood sampling;\n* specific visit in case of hospitalization for infectious events or adverse effects of vaccination, exacerbation or new diagnosis of auto-immune disease, new diagnosis of cancer, or SARS-CoV-2 infection whether or not patients are admitted to hospital, with blood sampling.\n\nIn addition, a retrospective \"passive\" follow-up will be implemented through matching with the data from the SNDS (National Health Data System), in order to collect clinical events of and healthcare resource consumption. Moreover, matching with controls adults from the national CONSTANCES cohort, not carrying auto-Abs against type I IFNs nor IEI-IFN-I, will be performed. (ratio 3:1; matching on age (+\u002F- 5 years), gender and geographic region of recruitment). Individuals under long-lasting immunosuppressive or immunomodulatory drugs will not be eligible. Follow-up of controls, which will be carried out as part of the CONSTANCES cohort, will include web-based questionnaires, every 12 months, in addition to linking with SNDS data as already done in this cohort.\n\nInclusion visit:\n\nAfter signing the consent form, the following tests will be performed:\n\n* Demographic characteristics (sex, age, country of birth)\n* Medical history from participant and family member(s) including infectious and auto-immune diseases, cancers and vaccination status and side effects\n* Blood samples for:\n\n  * full blood cell count;\n  * classical autoimmune investigations (anti-nuclear, anti-ENA, native anti-DNA, anti- thyroid antibodies, rheumatoid factor);\n  * immunophenotyping\\*;\n  * auto-Abs against type I IFNs, other cytokines\\*, or other target proteins\\* (dosage and neutralization activity);\n  * Genetic explorations by whole-exome or whole-genome sequencing\\*;\n  * Biobanking (DNA, plasma\u002Fsera; cryopreserved peripheral blood mononuclear cells (PBMCs).\n\n    * these biological analyses will be carried out as part of dedicated COVIFERON RHU5 workpackages.\n\nIn addition, vaccination against SARS-CoV-2 and influenza will be offered to these subjects as a priority, as part of their usual care.\n\nFollow-up visits :\n\nAnnual visits to the CIC :\n\n* Medical history since last visit, including infectious, auto-immune and oncologic events, vaccination status and side effects\n* Blood samples for:\n\n  * full blood cell count;\n  * classical autoimmune investigation (anti-nuclear, anti-ENA, native anti- DNA, anti-thyroid antibodies, rheumatoid factor);\n  * immunophenotyping;\n  * Auto-Abs against type I IFNs, other cytokines, or other target proteins (dosage and neutralization)\n  * Biobanking (DNA, plasma, cryopreserved peripheral blood mononuclear cells (PBMCs))\n\nAdditional specific visit in the event of a clinical event of interest, at any time during follow-up:\n\n* In case of SARS-CoV-2 infection, whatever the severity of the disease: blood sampling for determination and neutralization of type I anti-IFN autoAbs, CBC, and biobanking (plasma and PBMC) and teleconsultation with the CIC in charge of patients, as soon as possible.\n* In the event of hospitalization for infectious events or exacerbation or new diagnosis of an auto-immune disease: blood sampling for determination and neutralization of anti-IFN-I autoAbs, CBC, and biobanking (plasma and PBMCs) and collection of the hospitalization report in the case report form on a dedicated page.",[26,27,28,29],"Immunology","Allergy","Genetic Diseases","Infectious Diseases",[31,32,33,34,35],"covid-19","auto-immunity","Type I interferon","kinetics","infectious diseases","RECRUITING","2025-09-02",{"date":39,"type":40},"2025-09-08","ACTUAL",{"date":42,"type":40},"2025-04-09",{"date":44,"type":21},"2029-01",{"name":46,"class":47},"Institut National de la Santé Et de la Recherche Médicale, France","OTHER_GOV",9,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":76},"100601951","early-phase-1-a-clinical-study-to-evaluate-the-safety-and-efficacy-of-anti-human-cd-7-car-nk-cell-injection-in-subjects-with-relapsed-and-refractory-cd7-positive-hematological-malignancy-100601951","NCT07117175","A Clinical Study to Evaluate the Safety and Efficacy of Anti-human CD 7 CAR-NK Cell Injection in Subjects With Relapsed and Refractory CD7-positive Hematological Malignancy","Inclusion Criteria:\n\n* Age 18-70 years old, gender is not limited;\n* The expected survival time exceeds 12 weeks;\n* ECOG score 0 to 2 points;\n* Comply with the 2022 WHO standards for acute myeloid leukemia (AML), lymphoblastic lymphoma\u002Fleukemia (LBL\u002FALL), and after testing, CD7-positive flow cytometry leukemia cells expressed CD7 by ≥70%; or immunohistochemical leukemia cells expressed CD7 ≥50%. At the same time, it meets the following relapse-refractory standards:\n\n  1. Recurrence criteria: ≥5% of the original cells appear in the bone marrow after hematologic remission (except for the hematopoietic recovery period after chemotherapy); or 2 peripheral blood samples at least one week intervals; or extramedullary lesions appear. Patients with early relapse (recuring within 12 months after the first remission) can be directly enrolled, while patients with advanced relapse (recuring after the first remission) need to rescue at least one course of chemotherapy through the original effective induction regimen and no remission is achieved; all relapse patients should include selectable targeted drugs for at least one course of treatment without remission. Allogeneic hematopoietic stem cells recur after transplantation, no other effective treatment options are available, and there is no active acute graft-versus-host disease (GVHD) above 2 degrees.\n  2. Refractory criteria: Complete remission was not achieved at the end of induction therapy, and complete remission was not achieved after second-line rescue chemotherapy or the treatment regimen containing optional targeted drugs. Patients with tumor burden exceeding 5%, patients with persistent micro-residual lesions (MRD) positive, or patients with extramedullary lesions are also considered eligible.\n* The intravenous pathway required for collection can be established, without contraindications for white blood cell collection;\n* Liver and kidney function and cardiopulmonary function meet the following requirements:\n\n  1. Creatinine clearance (calculated by Cockcroft Gault formula) ≥60 mL\u002Fmin or creatinine ≤2.5×ULN;\n  2. The cardiac ejaculation fraction is greater than 50%, and there is no clinically significant electrocardiogram change;\n  3. Baseline blood oxygen saturation is greater than 92%;\n  4. Total bilirubin ≤3×ULN; ALT and AST ≤3×ULN;\n* Be able to understand this test and have signed an informed consent form.\n\nExclusion Criteria:\n\n* Use of immunosuppressive drugs or steroids within two weeks prior to cell collection, or the need for steroid or immunosuppressive drug use for more than two years.\n* History of malignancy other than hematologic neoplasms within five years before screening, except for adequately treated cervical carcinoma in situ, basal cell, or squamous cell skin cancer, localized prostate cancer after curative surgery, ductal carcinoma in situ after curative surgery, and thyroid cancer after curative surgery;\n* Active bacterial, viral, or fungal infections requiring treatment and not controlled; positive HBsAg or HBcAb (if positive, peripheral HBV-DNA testing is required with HBV DNA \\\u003C detection limit to be eligible); positive HCV antibody with peripheral blood HCV RNA positivity; positive Treponema pallidum particle assay (TPPA); HIV antibody positivity;\n* Inadequate function of major organs (cardiovascular system, lungs), active gastrointestinal bleeding within the past three months; uncontrolled hypertension or history of hypertensive crisis or hypertensive encephalopathy; significant cardiovascular risk history or evidence including any of the following: congestive heart failure, unstable angina pectoris, clinically significant arrhythmias (such as ventricular fibrillation, ventricular tachycardia); history of arterial thrombosis formation within the last three months (such as stroke, transient ischemic attack); symptomatic deep vein thrombosis or pulmonary embolism within six months prior to enrollment; previous coronary angioplasty procedure; cardioversion by electric shock; any clinically relevant complications that may pose a risk to the safety of the subject or interfere with study assessments, procedures, or completion;\n* Any uncontrolled active disease that would preclude participation in the trial;\n* Active and uncontrolled central nervous system involvement by disease process or a history thereof requiring treatment (e.g., epilepsy);\n* Subjects receiving systemic corticosteroid therapy at screening who are expected to require long-term systemic corticosteroid therapy during the course of the study (inhaled and topical use excluded);\n* Subjects who have used PD-1\u002FPD-L1 monoclonal antibodies within three months prior to enrollment;\n* Pregnant women and those lactating; subjects planning pregnancy within one year post-infusion or during\u002Fafter treatment;\n* Presence of uncontrollable active infection (simple urinary tract infection and upper respiratory tract infection excluded);\n* Previous receipt of CAR-T\u002FCAR-NK therapy or other genetically modified cellular therapies;\n* Allogeneic transplant recipients without evident acute\u002Fchronic graft-versus-host disease and off immunosuppressive drugs for at least one month;\n* Known allergy to any component of anti-human CD7 CAR-NK cell injection solution or chemotherapy regimen (cyclophosphamide and fludarabine);\n* Any condition deemed by the investigator as likely to impair subject safety or interfere with study objectives; subjects considered unsuitable for this trial by investigators.\n* Subjects unable to provide written informed consent due to illness affecting their ability to do so; unwillingness or inability to comply with study requirements.","70 Years",{"count":57,"type":21},18,"INTERVENTIONAL",[60],"EARLY_PHASE1","This study is a single-arm, open-label, dose-escalation clinical trial to explore the safety, tolerability, pharmacokinetics and pharmacodynamics characteristics of the drug; The efficacy of the study drug in subjects with relapsed\u002Frefractory CD7-positive hematological malignancies, and the expression of B cells, T cells, and NK cell subtypes in peripheral blood were preliminarily observed. At the same time, explporing the distribution of anti-human CD7 CAR-NK cells in tumor tissues after administration of anti-human CD7 CAR-NK cell injection, and evaluating the immunogenicity of anti-human CD7 CAR-NK cell injection . To evaluate the correlation between the proportion of CD7-positive tumor cells and the safety and efficacy of anti-human CD7 CAR-NK cell injection and the evaluation. To explore the pharmacokinetics (PK) and pharmacodynamics(PD) characteristics of bone marrow in Chinese medicine.",[26,63,64],"Hematologic Malignancies","CAR-NK","NOT_YET_RECRUITING","2025-08-10",{"date":68,"type":40},"2025-08-12",{"date":70,"type":21},"2025-09-01",{"date":72,"type":21},"2028-01-30",{"name":74,"class":75},"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","OTHER",1,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":58,"phases":86,"briefSummary":88,"conditions":89,"keywords":91,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":4},"100589596","bmemhla--origins-of-the-heterogeneity-of-the-anti-hla-memory-b-cells-in-kidney-transplantation-100589596","NCT06956469","BmemHLA : Origins of the Heterogeneity of the Anti-HLA Memory B Cells in Kidney Transplantation","BmemHLA","Inclusion Criteria:\n\n* Adult kidney transplantation candidate at CHU de Bordeaux\n* Sensitized against class I HLA\n* Only on type of sensitizing event among : transfusion, pregnancy, previous transplantation, no senitizing event\n\nExclusion Criteria:\n\n* Pediatric kidney transplantation candidate at CHU de Bordeaux\n* Rituximab injection\n* Ongoing treatment with immunosuppressive drugs\n* Non-cutaneous carcinoma, chronic viral infection\n* Acute infection\n* Recent vaccination (\\\u003C1 month)",{"count":85,"type":21},75,[87],"NA","This study will describe the transcriptomic and phenotypic characteristics of anti-HLA memory B cells by comparing five groups of patients awaiting renal transplantation: patients with a single history of pregnancy, transfusion or failure of a first renal transplant requiring transplantectomy within 3 months of transplantation, or after 3 months, and patients without an immunizing allogeneic event. The hypothesis is that these five contexts induce different types of memory B cells with different modalities of reactivation and post-transplant pathogenicity.",[90,26],"Kidney Transplantation",[92,93,94,95,96],"Kidney","Memory B Cell","Anti-HLA antibodies","Allogeneic events","Transplantation","2025-05-26",{"date":99,"type":40},"2025-05-28",{"date":101,"type":21},"2025-06-15",{"date":103,"type":21},"2028-12-15",{"name":105,"class":75},"University Hospital, Bordeaux",{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":113,"enrollmentInfo":114,"targetDuration":4,"studyType":58,"phases":116,"briefSummary":118,"conditions":119,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":4},"100587181","phase-2-shr0302-combined-with-pd-1pd-l1-inhibition-for-treatment-nave-or-acquired-resistant-to-immunology-nsclc-100587181","NCT06925048","SHR0302 Combined With PD-1\u002FPD-L1 Inhibition for Treatment naïve or Acquired Resistant to Immunology NSCLC","A Multi-cohort, Phase II Study of SHR0302 Combined With PD-1\u002FPD-L1 Inhibition for Treatment naïve or Acquired Resistant to Immunology NSCLC","Inclusion Criteria:\n\n1. Inoperable or non-suitable for radical radiotherapy and chemotherapy IIIB\u002FIIIC and Stage IV or metastatic non-small cell lung cancer (NSCLC)\n2. Provide written informed consent for the trial.\n3. Patients ≥ 18 years of age\n4. Arm 1: treatment naive; Arm 2: acquired resistant to first-line PD-1\u002FPD-L1 inhibition. Acquired resistance is defined as documented initial objective response (partial or complete response by RECIST or WHO) to therapy or significant and durable (\\> 6 months) clinical benefit (stable disease defined by RECIST or WHO).\n5. Subject must have adequate tumor burden at a safely accessible site for biopsy.\n6. At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1\n7. ECOG performance status 0 or 1\n8. Adequate organ function:\n\n(1) White Blood Cell ≥3.0×109\u002FL; Absolute neutrophil count (ANC) ≥ 1.5×10\\*9 \u002FL; Platelets ≥ 100×10\\*9 \u002FL; Hemoglobin ≥ 9g\u002Fdl; (2) Serum creatinine ≤1.5 X upper limit of normal or creatinine clearance ≥ 40 mL\u002Fmin; (3) Serum total bilirubin ≤ 1.5 X ULN; AST and ALT ≤ 2.5 X ULN OR ≤ 5 X ULN for subjects with liver metastases; 9. Subjects of reproductive potential must agree to use acceptable birth control methods\n\nExclusion Criteria:\n\n1. Non-small cell cancer contains components of small cell lung cancer or neuroendocrine carcinoma.\n2. Sensitizing mutations in Epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) or ROS1 proto-oncogene receptor tyrosine kinase (ROS1) translocations;\n3. Arm 1: Currently participating in or has participated in a study of an investigational agent or anticipated use of an investigational device within 4 weeks of the first dose of study treatment.\n4. Receiving Chinese patent medicines with anti-tumor indications or drugs with immunomodulatory effects within 2 weeks before the first administration.\n5. Having a history of allergic reaction to any component of the study drug.\n6. Having active hemoptysis requiring clinical intervention, active diverticulitis, abdominal abscess, gastrointestinal obstruction, and peritoneal metastasis.\n7. Having clinically uncontrollable pleural effusion\u002Fabdominal effusion (patients who do not need to drain the effusion or whose effusion does not increase significantly within 3 days after stopping drainage can be enrolled).\n8. The tumor compressing surrounding vital organs (such as the esophagus) and accompanied by related symptoms, compressing the superior vena cava or invading the large vessels in the mediastinum, the heart, etc.\n9. Severe comorbidities such as a history of severe lung or heart diseases, and having experienced any arterial thrombosis, embolism, or ischemia within 6 months before being selected for treatment, such as myocardial infarction, unstable angina pectoris, cerebrovascular accident, or transient ischemic attack, etc.\n10. Having a history of deep vein thrombosis, pulmonary embolism, or any other serious thromboembolism within 3 months before enrollment.\n11. Interstitial pneumonia (ILD), drug-induced pneumonia, radiation pneumonia requiring steroid treatment, or symptomatic active pneumonia.\n12. Receiving systemic corticosteroids (\\>10 mg\u002Fd prednisone equivalent drugs) or other systemic immunosuppressants within 2 weeks before enrollment. Local, ophthalmic, intra-articular, intranasal, and inhaled corticosteroids are allowed.\n13. A history of autoimmune diseases. Patients with autoimmune-related hypothyroidism who are receiving a stable dose of thyroid hormone replacement therapy are eligible to participate in this study. Patients with type 1 diabetes mellitus who are under control after receiving a stable insulin treatment regimen are eligible to participate in this study.\n14. Active systemic infection, including tuberculosis (clinical diagnosis includes clinical history, physical examination, and imaging findings, as well as TB examinations according to local medical routines), hepatitis B (known to be positive for HBV surface antigen (HBsAg) and HBV DNA ≥1000 cps\u002Fml or the lower limit of its reference value), hepatitis C, or human immunodeficiency virus (positive for HIV antibody).\n15. Known presence of mental illness or drug abuse that may affect compliance with the requirements of the trial.\n16. Recently receiving sufficient oral or non-oral anticoagulants or thrombolytics. Prophylactic use of anticoagulants is allowed.\n17. Having a medical history, disease, treatment, or laboratory abnormal results that may interfere with the trial results or prevent the subject from participating in the study throughout the whole process, or the investigator deems that participating in the study is not in the best interest of the subject.","75 Years",{"count":115,"type":21},86,[117],"PHASE2","Recent studies showed that the dysregulated activation of the JAK\u002FSTAT pathway, which leads to the prolonged release of IFN-γ, is a significant contributor to the resistance to immune checkpoint inhibitors in cancer immunotherapy. Preclinical and clinical studies have demonstrated that the combination of JAK inhibitors with PD-1 immunotherapy can reverse or delay onset of immunotherapy resistance by modulating the JAK\u002FSTAT pathway in Hodgkin's lymphoma and non - small cell lung cancer (NSCLC). SHR0302, being a highly selective JAK1 inhibitor, has shown excellent clinical benefits by effectively inhibiting the JAK\u002FSTAT pathway, leading to its approval for the treatment of Ankylosing Spondylitis in China. Preclinical studies also show that the combination of SHR0302 and PD-L1 inhibitor has synergistic potentials for anti-tumor effect in resistant to-immune checkpoint blockade patients. Thus, we conducted a phase 2 clinical trial evaluating SHR0302 combined with PD1\u002FPD-L1 inhibitors as treatment-naïve or acquired resistant to first-line checkpoint inhibitor resistant NSCLC patients.",[120,121,26],"Non-Small Cell Lung Cancer","JAK Inhibitor","2025-04-05",{"date":124,"type":40},"2025-04-13",{"date":126,"type":21},"2025-04-30",{"date":128,"type":21},"2027-12-31",{"name":130,"class":75},"Chunxia Su",{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":16,"sex":138,"minAge":18,"maxAge":4,"enrollmentInfo":139,"targetDuration":141,"studyType":23,"phases":4,"briefSummary":142,"conditions":143,"keywords":146,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":76},"100583939","immunomodulation-during-pregnancy-100583939","NCT06882850","Immunomodulation During Pregnancy","Immunomodulation During Pregnancy Through Low-Dose Aspirin: a Hypothetical Mechanism for the Prevention of Preeclampsia?","Inclusion Criteria: - Singleton pregnancy\n\n* Patients attending prenatal consultations at the Obstetrics Service A of CHUC, with the first consultation occurring before 14 weeks of gestation\n* Gestational age determined by first-trimester ultrasound\n* Study group: Women classified as high risk for PE according to clinical\u002Fhistorical criteria and the Fetal Medicine Foundation algorithm. LDA-naïve.\n\nExclusion Criteria: Multiple pregnancy\n\n* Autoimmune diseases\n* Prior use of LDA or other immunomodulatory medication before potential recruitment\n* History of spontaneous miscarriages and\u002For medical termination of pregnancy\n* Fetal malformation","FEMALE",{"count":140,"type":21},30,"30 Weeks","The goal of this observational study is to learn about the effects of low dose aspirin in immunity Pregnant women taking aspirin for other reasons (preeclampsia prevention) will be studied. The main question it aims to answer is: evaluate the effect of LDA on the modulation of innate immunity cells (NK cells, monocytes, γδ T cells) and\u002For acquired immunity (B and T lymphocytes, Treg cells, Th cells).\n\nParticipants already taking intervention A as part of their regular medical care for RA will answer online survey questions about their joint pain for 5 years.",[144,145,26],"Aspirin","Pregnancy Complications",[26,147,144,148,149],"Pregnancy","Lymphocytes","T-Lymphocytes","2025-03-15",{"date":152,"type":40},"2025-03-19",{"date":154,"type":40},"2024-02-01",{"date":156,"type":21},"2025-03-31",{"name":158,"class":75},"Unidade Local de Saúde de Coimbra, EPE"]